Radiation Oncology

The Department of Radiation Oncology actively collaborates in the multidisciplinary care of patients with cancer with the use of external beam radiation (e.g. electrons, IMRT, SBRT/SABR) and brachytherapy (e.g. HDR, eye-plaque, LDR) to treat tumors. As a team, we work with both surgeons and medical oncologists from all other disease sites including breast, CNS, pediatric, head and neck, thoracic and lung, sarcoma, genitourinary, gynecologic, gastrointestinal, lymphomatous, cutaneous malignancies, melanoma / Merkel cell, and ophthalmologic cancers as well as certain benign disorders (Dupuytren’s contracture, keloids). 

Our team focuses not only on novel radiation treatment delivery but also on technology to improve cancer care, research for prognosis, improving clinical and quality of life outcomes, as well as synergy with other treatments such as chemotherapy and immunotherapy. Multiple faculty and staff serve on national research committees and have active clinical, physics/technological, and basic science research. We participate in collaborative national and international trials. Radiation oncology is a full member of NRG, actively participates in SWOG as well as NTCN, and we are a NCI designated cancer center with state-of-the-art technology, including a new radiation treatment facility opened in 2018. 

Not only do we care about ensuring the best clinical outcomes and trying to achieve the highest cure rates, but we also care about the personal well-being of our patients and collaborate with supportive care, social work and other practitioners to provide a holistic approach to treatment. Part of delivering the best care possible is by offering innovative research programs and clinical trials. 

Please contact Alysha Zeoli at 520-694-4355 for more information.

Featured Clinical Trials

Maintenance Systemic Therapy Versus Consolidative Sterotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

NRG-DT001: A PHASE IB TRIAL OF NEOADJUVANT AMG 232 CONCURRENT WITH PREOPERATIVE RADIOTHERAPY IN WILD-TYPE P53 SOFT TISSUE SARCOMA (STS)

Phase II-III trial of adjuvant radiotherapy and androgen deprivation following radical prostatectomy with or without adjuvant Docetaxel

Tucson

Radiation Oncology
Victor J Gonzalez, MD
Radiation Oncology
Radiation Oncology
Radiation Oncology
Radiation Oncology
Baldassarre Stea, MD, PhD
Radiation Oncology
Interventional Radiology
Sun K Yi, MD
Radiation Oncology

Phoenix

Radiation Oncology
Radiation Oncology

Staff

Phoenix

Clinical Research Coordination

Sarah Shilling

Regulatory Coordination

Ramses Pardo
602-827-2683
Tucson

Clinical Research Coordination

Alejandro Romero, BSHS
520-694-2347

Research Data Coordination

Veronica Salaiz
520-694-4355

Regulatory Coordination

Angelica Erunez
520-626-6931